Cargando…
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
Chimeric antigen receptor (CAR)‐T cell therapy is now approved in the United States and Europe as a standard treatment for relapsed/refractory B‐cell malignancies. It has also been approved recently by the Therapeutic Goods Administration in Australia and may soon be publicly reimbursed. This advanc...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526894/ https://www.ncbi.nlm.nih.gov/pubmed/31139410 http://dx.doi.org/10.1002/cti2.1050 |